Beroni Logo @ Dec 2019.png
Beroni Group Published an Article Related to Single-Domain Antibodies in the FEBS Journal
October 28, 2021 08:30 ET | Beroni Group Limited
NEW YORK and SYDNEY, Australia, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based biopharmaceutical enterprise, today announced...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET | Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Global Healthcare Gamification Market Projected to Garner $47,281.5 Million Revenue by 2026, and Rise at a CAGR of 11.9% from 2019 to 2026 - Exclusive Report [120-Pages] by Research Dive
September 08, 2021 09:00 ET | Research Dive
New York, USA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Research Dive states that the global healthcare gamification market is anticipated to register a revenue of $47,281.5 million by 2026, at a CAGR of...
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
July 29, 2021 07:33 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Global Healthcare Gamification Market Estimated to Hit $47,281.5 Million and Grow with a Significant CAGR of 11.9% from 2019 to 2026 – Exclusive Report [120 Pages] By Research Dive
June 29, 2021 09:00 ET | Research Dive
New York, USA, June 29, 2021 (GLOBE NEWSWIRE) -- A latest report on the global healthcare gamification market has been added by Research Dive to its offerings. As per the report, the market is...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET | Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
Codex DNA Expands End-to-End Automated Synthetic Biology Workstation Enabling High Throughput Synthesis from DNA Sequence to Biologically Active mRNA
April 27, 2021 10:00 ET | Codex
San Diego, CA, April 27, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc., creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today...
Brain Scientific Announces Collaboration with JelikaLite in New Clinical Trial
March 16, 2021 08:30 ET | Brain Scientific Inc.
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, announces a collaboration...
Milestone Scientific LOGO.jpg
Milestone Scientific to Present at the Q1 Virtual Investor Summit
March 12, 2021 07:00 ET | Milestone Scientific Inc.
ROSELAND, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provides virtually...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
January 28, 2021 09:15 ET | Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the...